• Company
• Influenza epidemic and the launch of generic products
• by Kim, Jin-Gu Oct 28, 2022 05:55am

• Company
• The New Testament Era of Rosuzet and K-CAB
• by Chon, Seung-Hyun Oct 28, 2022 05:55am

• Policy
• The warning phrase deleting the possibility of Nucynta abuse
• by Lee, Hye-Kyung Oct 27, 2022 05:52am

• InterView
• "Lilly rises in anticancer and autoimmune diseases"
• by Eo, Yun-Ho Oct 27, 2022 05:52am

• Company
• Dexeryl for atopic dermatitis lands in Korea
• by Oct 27, 2022 05:52am

• Company
• The unfinished aftershocks of COVID-19
• by Chon, Seung-Hyun Oct 26, 2022 05:50am

• Company
• First TYK2 inhibitor Sotyktu will enter Korean market
• by Eo, Yun-Ho Oct 26, 2022 05:50am

• Policy
• Permission for Libtayo, a tx for skin squamous cell cancer
• by Lee, Hye-Kyung Oct 26, 2022 05:50am

• Company
• Xarelto sales fall 30% due to generics and price cuts
• by Oct 26, 2022 05:50am

• Policy
• Price cut of Faslodex
• by Lee, Tak-Sun Oct 26, 2022 05:50am